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Objectives:We investigated the relationships of recurrence site with the involved organ and cell type in patients
with Masaoka stage III thymomas.
Methods: Records of 84 patients who underwent a complete resection of stage III thymomas between 1957 and
2005 were reviewed and then divided according to involved organ. The number of patients with cell types deter-
mined according to World Health Organization criteria were 2, 5, 7, 37, and 7 for types A, AB, B1, B2, and B3,
respectively, whereas type was not determined in 25 patients.
Results: Lung invasion occurred in 58 patients, followed by invasion of the pericardium in 47 and invasion of the
great vessels in 23. Recurrence occurred in 23 patients, which included 12 with pleural dissemination and 8 with
distant metastasis, mostly in the lung. Lung invasion was seen in 8 of the 12 patients with pleural recurrence,
whereas vascular invasion was seen in 6 of the 8 patients with distant metastasis. Local recurrence was less com-
mon. Disease-free survival after 10 years for all subjects was 74.2%, whereas it was lower for those with vascular
invasion (46.1%) compared with those without invasion (87.1%, P< .05). Of the 23 patients with recurrence,
World Health Organization cell types B1, B2, and B3 were seen in 2, 11, and 3 cases, respectively, whereas
type was not determined in 7 patients.
Conclusions: The pleural cavity and lung are common sites of recurrence of Masaoka stage III thymomas. It is
important to establish an inclusive therapeutic strategy that considers the relationships of involved organs and
sites of recurrence in these patients.G
T
SThe clinical classification system of thymomas proposed by
Masaoka and associates1 has long been used as a prognostic
factor for patients with thymomas. Since surgical resection
has taken a pivotal role in the treatment of thymomas, vari-
ous investigations of the outcome of patients after resection
have been conducted to evaluate that treatment. Those stud-
ies have shown that the survival rate for patients with Ma-
saoka stage I and II thymomas is greater than 80% at 10
to 20 years.2-8 In contrast, the 10-year survival rate for pa-
tients with stage III disease in previous studies ranges
from 30% to 85%, whereas it is lower than 58% in patients
with stage IV disease. These results indicate that new thera-
peutic strategies should be developed to improve the out-
come of patients with thymomas in those advanced stages.
After reporting that patients with stage III disease and in-
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survival compared with those without involvement,9 we
considered that the site of recurrence is important for treat-
ment of patients with advanced stage thymomas, and eluci-
dation of those sites as related to involved organs might
contribute to improving the survival rate.
We previously reported that the histologic classification
system of thymomas proposed by the World Health Organi-
zation (WHO)10 was a significant prognostic factor for
patients with thymomas in addition to Masaoka clinical
staging,3 after which a number of authors confirmed our
findings with their patient data.4,6,7,11-13 In the present study
we examined the relationships of the site of recurrence with
the involved organs and with WHO histologic classification.
MATERIALS AND METHODS
We reviewed the records of 346 patients who underwent complete resec-
tion for a thymoma at Osaka University Hospital and its affiliated hospitals
during the 48-year period from 1957 to 2004. Patients with a final diagnosis
of thymic carcinoma and those who underwent a biopsy alone, as well as
those who received a resection with a macroscopic or microscopic residual
tumor, were not included. Of these 346 patients, 84 were classified as having
stage III disease in Masaoka’s staging system1 and were selected for the
present study. The subjects comprised 49 male and 35 female patients,
who ranged in age from 20 to 83 years (mean, 51 years). Chemotherapy
was administered in 16 patients: 8 preoperatively and 8 postoperatively. Ra-
diation therapy was performed in 64 patients: 9 preoperatively, 55 postop-
eratively, and 1 both preoperatively and postoperatively.
The involved organs were determined after a critical review of the
operative records, and involvement of the great vessels (V), lungs (L),
and pericardium (P) was evaluated. Thus a total of 7 groups of subjects
were generated: V(þ)L(þ)P(þ), V(þ)L(þ)P(), V(þ)L()P(þ), V()L(þ)P(þ),
V(þ)L()P(), V()L(þ)P(), and V()L()P(þ), where (þ) indicates existencerdiovascular Surgery c Volume 136, Number 6 1481






V ¼ great vessels
WHO ¼ World Health Organization
of involvement and () indicates no involvement. For analyzing disease-free
survival, the subjects were assigned to one of 3 groups, V(þ)L(þ or)P(þ
or), V()L(þ)P(þ or), and V()L()P(þ) because some groups had too
few members to effectively perform a statistical analysis.
There were no strict rules for postoperative follow-up; however, it was
common to obtain computed tomograms of the chest once a year. In the
era before computed tomography was available, chest radiographic analysis
was performed once or twice a year. Recurrence was diagnosed based on
imaging or pathologic examinations by reviewing the subject records.
When recurrence was detected at multiple sites, each was recorded as
such. The interval between resection of the thymoma and detection of recur-
rence was calculated. When a patient died of other diseases than thymoma,
he or she was treated as a censored case at the time of death.
Pathologic examinations were performed with hematoxylin and eosin–
stained sections derived from paraffin-embedded blocks. Histologic diagno-
sis with reference to the WHO classification system was performed to
distribute the cases into cell types A, AB, B1, B2, and B3, and then recur-
rence rates with reference to the WHO cell types were determined. The
relationships between the WHO cell type and involved organs and between
cell type and interval from resection to recurrence were also examined.
Recurrence rates were compared among each group by using a c2 test.
Actuarial disease-free survival rates were calculated with the Kaplan–Meier
method, and statistical differences between survival curves were examined
with a log-rank test. In case there were 3 or more groups to be compared,
a multiple comparison test was performed. Statistical analyses were per-
formed with the personal computer software StatView 5 (SAS Institute,
Inc, Cary, NC).
RESULTS
The number of patients in each category of involved or-
gans is indicated in Table 1. Among the 84 patients, invasion
into the great vessels, lungs, and pericardium was seen in 23,
58, and 47 patients, respectively, including duplication. Fur-
thermore, invasion into 1, 2, and 3 organs was seen in 48, 25,
and 10 patients, respectively. In the 23 patients with invasion
into the great vessels, sites of invasion included the left in-
nominate vein, the superior vena cava, or both. Invasion
into the aorta was seen in 2 patients, and in both it remained
at the adventitia. In the 58 patients with lung invasion,
wedge resections were performed for all but one.
Tumor recurrence occurred in 23 of 84 patients. A review
of recurrence rates according to the presence or absence of
involvement of each category of organs showed 12 recur-
rences in the 23 cases that involved the great vessels
(52.2%), whereas there were 11 recurrences in 61 patients
without that involvement (18.3%, P ¼ .002). In the same
manner, 17 recurrences were found in the 58 patients with
lung involvement (29.3%), whereas 6 were found in the
26 patients without involvement (23.1%, P ¼ .55), and 10
recurrences were found in the 47 patients with pericardial in-1482 The Journal of Thoracic and Cardiovascular Suvolvement (21.3%), whereas 13 were found in the 37 pa-
tients without involvement (35.1%, P ¼ .16).
The patterns of recurrence were pleural dissemination in
12, distant metastases in 8, and local recurrence in 6 patients,
including duplication. Organs with metastasis were the lung
in 6 patients and in 1 patient each for the liver and brain.
Among the 6 patients with local recurrence, 2 experienced
local recurrence only, whereas the other 4 had pleural dis-
semination, distant metastasis, or both along with local re-
currence.
The relationships between the involved organs when re-
sected and the sites of recurrence were also analyzed. Among
8 cases that recurred as distant metastasis, involvement of the
great vessels was seen in 6, whereas the other 2 cases in-
volved the lung, which was resected, and also recurred in
the lung. On the other hand, of the 12 patients who had recur-
rence as pleural dissemination, involvement of the lung was
seen in 9 patients, and the great vessels, with or without peri-
cardial involvement, were involved in the other 3 patients.
Actuarial disease-free 10- and 20-year survival rates for
the whole population were 74.6% and 58.7%, respectively.
Grouped disease-free survival curves divided by the in-
volved organs are shown in Figure 1. The disease-free sur-
vival curves for the 4 groups with involvement of the great
vessels were similar, regardless of whether additional organs
were involved. In an analysis of the V(þ)L(þor)P(þor),
V()L(þ)P(þor), and V()L()P(þ) groups, the 20-year dis-
ease-free survival rates were 46.1%, 53.4%, and 93.3%, re-
spectively (P ¼ .0082). The differences in disease-free
survival between the V(þ)L(þor)P(þor) groups and the
other groups were important (P¼ .0078 and .0270), whereas
that between the V()L(þ)P(þor) and V()L()P(þ) groups
was not (P ¼ .2106).
Adjuvant radiation therapy was used in 19 of the 23 pa-
tients with involvement of the great vessels and 45 of
the 61 patients without involvement (P ¼ .5672). Grouped
TABLE 1. Involved organs and patterns of recurrence of Masaoka’s
stage III thymomas
Involved organs
V L P n (recurrence) Patterns (n)
þ þ þ 10 (5) PD (4), lung (1)
þ þ  5 (2) Lungþ local (1), brain (1)
þ  þ 4 (3) Lung (2) PDþ liverþ
local (1)
 þ þ 16 (1) Pericardial dissemination
þ   4 (2) PDþ local (1), PD (1)
 þ  27 (9) PD (4), PDþ local (1),
lung (2), local (1)
  þ 17 (1) Local (1)
Not recorded 1
Total 84 (23)
V, Great vessels; L, lungs; P, pericardium;þ, existence of involvement;, nonexistence
of involvement; PD, pleural dissemination.rgery c December 2008
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SFIGURE 1. Actuarial survival curves of patients with involvement of the great vessels (A), lung (B), and pericardium (C), as well as for all patients (D). In
each panel,þindicates cases with involvement of the specified organ,indicates those without involvement, andþorindicates those with and without such
involvement. V, Great vessels; L, lung; P, pericardium.20-year disease-free survival rates divided by the presence
and the absence of radiation therapy were 54.4% for the for-
mer and 66.3% for the latter (P ¼ .9794). Local recurrence
occurred in 5 patients in the former and 1 patient in the latter
groups (P> .9999).
To examine the effect of long duration of the present
study, the subjects were divided into one of 2 groups: one in-
cluded those who underwent resection before 1990 (n¼ 41),
and the other included those who underwent resection after
1991 (n ¼ 43). The 10-year disease-free survival rates were
78.4% and 67.5% for the former and the latter, respectively
(P¼ .4646). For those with involvement of the great vessels,
they were 50.8% and 42.4%, respectively (P ¼ .8582).
WHO cell type was identified in 58 patients (Table 2). The
number of patients with type B2 cells had the greatest fre-
quency (at 63.7%) of cases with known WHO cell types,
followed by types B1 and B3 (at 12.1% each). Cell types
AB and A were seen less commonly. Although the number
of patients was small, there was no recurrence in patients
with cell types A and AB. The recurrence rates for cell types
B1, B2, and B3 were 28.6%, 29.7%, and 42.9%, respec-
tively, with the differences not important, whereas actuarial
disease-free survival was also similar among patients with
those 3 cell types (P ¼ .96, Figure 2).The Journal of Thoracic and CDISCUSSION
There are several reports regarding thymoma recur-
rence.8,14,15 However, to the best of our knowledge, the pres-
ent study is the first to focus on the relationships among
involved organs and sites of recurrence.
In our series, pleural dissemination was the most frequent
pattern of recurrence in Masaoka stage III thymomas, fol-
lowed by distant metastasis. Many cases of recurrence in
the pleura arose from those that originally showed involve-
ment of the lung. The biologic mechanism by which pleural
dissemination occurs more often than distant metastasis has
yet to be clarified; however, previous studies of thymoma re-
currence also noted that recurrence in the pleural cavity was
seen the most often.8,14,15 As for the reason for frequent re-
currence in the pleura, we considered that thymomas with
lung invasion must pass through the mediastinal pleura
while they grow to be exposed on the surface of the thoracic
cavity and invade the lung because the thymus is originally
located in the anterior mediastinum. Thus it is more likely
that thymomas with involvement of the lung coexist with
disseminated tumor cells in the thorax compared with those
without thoracic exposure, even if the disseminated lesions
cannot be seen by means of diagnostic imaging or macro-
scopic inspection at a thoracotomy.ardiovascular Surgery c Volume 136, Number 6 1483
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STABLE 2. Relationships of involved organs and WHO cell types and recurrence of Masaoka’s stage III thymomas
Involved organs WHO cell types
V L P A AB B1 B2 B3 ND Total
þ þ þ 1 1 6 (4) 2 (1) 10 (5)
þ þ  1 2 (1) 1 (1) 1 5 (2)
þ  þ 1 1 (1) 1 (1) 1 (1) 4 (3)
 þ þ 3 4 (1) 3 6 16 (1)
þ   1 3 (2) 4 (2)
 þ  1 1 1 (1) 15 (4) 1 (1) 8 (3) 27 (9)
  þ 2 2 (1) 8 1 4 17 (1)
Total 2 5 7 (2) 37 (11) 7 (3) 25 (7) 83 (23)
Numbers in brackets indicate the number of patients with recurrence.WHO, World Health Organization; V, great vessels; L, lungs; P, pericardium; ND, not determined;þ, existence
of involvement;, nonexistence of involvement.Distant metastasis often occurs in cases with involvement
of the great vessels, most frequently in the lungs. It is likely
that the lung is the nearest organ with a capillary system for
tumor cells to encounter because the left innominate vein is
the most common great vessel involved. It is understandable
that tumor cells would pass through the superior vena cava,
right atrium and ventricle, and pulmonary artery before be-
ing scattered in the pulmonary capillaries and become im-
planted there to grow as a metastatic lesion. Although it
remains as speculation, it seems important to place more em-
phasis on detecting recurrent lesions in the thorax, rather
than in the bone, brain, or abdomen, when performing fol-
low-up examinations of patients.
The present study revealed that the recurrence rate was
greater and disease-free survival shorter in cases involving
the great vessels compared with those without that involve-
ment. In addition, when the great vessels are not involved,
disease-free survival was similar, regardless of involvement
of the lung and pericardium. Therefore the presence or
FIGURE 2. Actuarial survival curves of patients with WHO cell types B1,
B2, and B3.1484 The Journal of Thoracic and Cardiovascular Sabsence of involvement of the great vessels might be of
prognostic significance for determining the recurrence of
thymomas. On the other hand, Wright and associates8 ana-
lyzed 179 thymic epithelial tumors, including 45 Masaoka
stage III cases and 11 stage IV cases, and reported that the
involved organ did not predict recurrence. We considered
some possible reasons for this discrepancy. The patient pop-
ulation in their report included both those with thymomas
and those with thymic carcinomas, whereas the present
study focused exclusively on thymomas. This difference
might have significantly affected the outcome of each study.
It is also possible that the difference in the number of patients
in both studies, which was greater in the present study, might
have affected the statistical results. Based on these 2 reasons,
both of which are important in regard to the study popula-
tions, we would suppose that the results in the present study
compare favorably with those in the report of Wright and
associates.
The pattern of recurrence for stage III thymomas found in
the present study might affect the planning of adjuvant ther-
apy for those patients. To date, postoperative radiation ther-
apy to the mediastinum has been the most popular in our
institution; however, local recurrence without pleural dis-
semination or distant metastasis was rare in the present
study. Furthermore, perioperative radiation therapy did not
have an effect on disease-free survival in our subjects, and
the local recurrence rate for subjects with radiation therapy
was the same as that for those without radiation therapy.
Thus it seems reasonable to make use of systemic therapies
rather than local ones to reduce the risk of pleural dissemina-
tion and distant metastases. On the other hand, patients with
recurrent thymomas might benefit from re–resection.16
Therefore the significance of postoperative radiation therapy
might require re-evaluation.
Recently, there have been reports describing that a multi-
modality therapy, including induction chemotherapy and
surgical intervention with or without a postoperative therapy
for stage III thymomas, might improve outcomes.17-19 We
found the subjects in the present study not appropriate for
discussing the effect of induction chemotherapy because iturgery c December 2008
Utsumi et al General Thoracic Surgery
G
T
Swas given only in the patients who were considered not re-
sectable in the preoperative assessments. However, the sig-
nificance of induction chemotherapy should be properly
evaluated, especially in the patients with invasion into the
great vessels because their prognoses were poor.
No recurrence was detected in patients with WHO cell
types A and AB, which is consistent with observations re-
ported by Wright and associates.8 Furthermore, recurrence
rates and disease-free survival were similar among cell types
B1, B2, and B3. This result was somewhat unexpected be-
cause it has been generally accepted that WHO cell type is
an independent prognostic factor for thymomas. Although
our series of thymomas is likely the largest one studied to
date, the number of patients is still insufficient to show sta-
tistical relevance, and another study conducted in a multi-
institutional setting might be required. Nevertheless, it is
worthwhile to keep in mind, when following patients with
Masaoka stage III thymomas, that cell types B1, B2, and
B3 might represent a higher risk of recurrence compared
with cell types A and AB.
The limitations of the present study include its retrospec-
tive nature and the long duration of patient collection. Fur-
thermore, developments of diagnostic techniques, such as
computed tomography, and of surgical devices have caused
changes in both the diagnosis and treatment of thymomas,
which might have skewed the results of the present study.
In conclusion, pleural dissemination and lung metastasis
were the 2 most frequent sites of recurrence in patients
with completely resected stage III thymomas, and the site
of recurrence was shown to be affected by the involved
organs. Thus stage III thymomas are thought to include
heterogenous subgroups, and an adjuvant treatment strategy
for patients with these tumors should be determined by
considering the involved organs.
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